Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysis

Emerging evidence has shown that miRNAs participate in human carcinogenesis as tumor suppressors or oncogenes, and have prognostic value for patients with cancers. In recent years, the miR-181 family was found dysregulated in a variety of human cancers and significantly associated with clinical outc...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013-03, Vol.8 (3), p.e59532
Main Authors: Lin, Shenglong, Pan, Lili, Guo, Shicheng, Wu, Junjie, Jin, Li, Wang, Jiu-Cun, Wang, Shaoyuan
Format: Article
Language:English
Subjects:
Analysis
Apoptosis
Biology
Blood cancer
Cancer
Cancer patients
Carcinogenesis
Carcinogens
Cell adhesion & migration
Education
Filtration
Gene expression
Genetic engineering
Hematologic Neoplasms - genetics
Hematologic Neoplasms - pathology
Hematology
Humans
Identification methods
Laboratories
Leukemia
Life sciences
Lymphoma
Medical ethics
Medical prognosis
Medicine
Meta-analysis
MicroRNA
MicroRNAs
MicroRNAs - genetics
MicroRNAs - metabolism
miRNA
Patients
Prognosis
Proteins
Ribonucleic acid
RNA
Studies
Subgroups
Suppressors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Emerging evidence has shown that miRNAs participate in human carcinogenesis as tumor suppressors or oncogenes, and have prognostic value for patients with cancers. In recent years, the miR-181 family was found dysregulated in a variety of human cancers and significantly associated with clinical outcome of cancerous patients. MiR-181a and miR-181b (miR-181a/b) were the most investigated members in the family. However, the results of miR-181a/b from different studies were inconsistent. Therefore, we performed a meta-analysis to summarize all the results from available studies, aiming to delineate the prognostic role of miR-181a/b in human cancers. The identified articles were retrieved from the two main on-line databases, PubMed and EMBASE. We extracted and estimated the hazard ratios (HRs) for overall survival (OS), which compared the high and low expression levels of miR-181a/b in patients of the available studies. Each individual HR was used to calculate the pooled HR. Eleven studies of 1252 patients were selected into the final meta-analysis after a strict filtering and qualifying process. Fixed model or random model method was chosen depending on the heterogeneity between the studies. The subgroup analysis showed that high expressed miR-181a/b could prolong OS in patients with hematological malignancies rather than low expression level (HR = 0.717, P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0059532